close

Fundraisings and IPOs

Date: 2011-06-13

Type of information: Capital increase

Company: Neovacs (France)

Investors: The shares were placed with 37 investors.

Amount: €7.6 million

Funding type: The capital increase took place via a private placing,

Planned used:

The funds raised strengthen Neovacs’s financial position and allow it to continue the development of the two Kinoid product candidates on which Neovacs is focused, the TNF-Kinoid and the IFN?-Kinoid.

Others:

Neovacs has completed its private placing initiated on June 7th, 2011. This capital increase is being undertaken in the context of the authority granted to the Board of Directors under the 12th resolution of the general meeting of shareholders, held on the 4th of May 2011. This capital increase is in addition to the € 2.25 million raised in April 2011 from Debioinnovation, Truffle Capital et OTC Asset Management at a price of 4 € a share, as well as the support received for the TRACKER program (€1.448 million) from Oseo and the Research Tax Credit (€1.3 million). The number of the Company’s shares outstanding will therefore be increased from this date by 1,900,091 shares and the total outstanding will rise from 13,554,173 to 15,454,264. Shareholders’s funds are increased from 5.4 M to 13.0 M€ based on the consolidated figures as at 30th April 2011.

Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases

Is general: Yes